tiprankstipranks
Trending News
More News >

Veritas In Silico’s Strategic Shift to Specialty Pharma

Veritas In Silico Inc. (JP:130A) has released an update.

Veritas In Silico Inc. is focused on expanding its platform business for mRNA-targeted drug discovery through strategic contracts and in-house pipeline creation. The company aims to enhance shareholder value by transitioning into a specialty pharmaceutical company with a balanced approach of revenue generation and investment.

For further insights into JP:130A stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App